Browse ADMET evidence entries by endpoint, reported value, assay context, interpretation role, and reference link. These counts indicate evidence availability, not safety, efficacy, or confidence by themselves.
Endpoints
17
·
Context signals
3,678
Measurements
39,523
Interpretation: Record counts indicate evidence availability, not safety, efficacy, or confidence by themselves. Use the ADMET-domain index and role filters to narrow the evidence-entry table before comparing values.
TGA Product Information pharmacokinetics manual extractionplasmahumansubcutaneoussteady statemultiple subcutaneous 1.5 mg doses in patients with type 2 diabetes
EU Clinical Trials Register PKD11475 results manual extractionplasmahumansubcutaneousday 1single 5 mcg lixisenatide; paediatric patients with type 2 diabetes; N=8; sampling through 6.5 hours post-dose
EU Clinical Trials Register PKD11475 results manual extractionplasmahumansubcutaneousday 1single 10 mcg lixisenatide; paediatric patients with type 2 diabetes; N=8; sampling through 6.5 hours post-dose
EU Clinical Trials Register PKD11475 results manual extractionplasmahumansubcutaneousday 1single 5 mcg lixisenatide; adult patients with type 2 diabetes; N=10; sampling through 6.5 hours post-dose
EU Clinical Trials Register PKD11475 results manual extractionplasmahumansubcutaneousday 1single 10 mcg lixisenatide; adult patients with type 2 diabetes; N=10; sampling through 6.5 hours post-dose
Cmax in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 1 of cycle 1 by LC-MS/MS analysishumaniv
Cmax in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysishumaniv
